The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease

E Ilijic, JN Guzman, DJ Surmeier - Neurobiology of disease, 2011 - Elsevier
The motor symptoms of Parkinson's disease (PD) are due to the progressive loss of
dopamine (DA) neurons in substantia nigra pars compacta (SNc). Nothing is known to slow …

Lower affinity of isradipine for L-type Ca2+ channels during substantia nigra dopamine neuron-like activity: implications for neuroprotection in Parkinson's disease

NJ Ortner, G Bock, A Dougalis… - Journal of …, 2017 - Soc Neuroscience
Ca2+-influx through L-type Ca2+-channels (LTCCs) is associated with activity-related
stressful oscillations of Ca2+ levels within dopaminergic (DA) neurons in the substantia …

The potential of L-type calcium channels as a drug target for neuroprotective therapy in Parkinson's disease

B Liss, J Striessnig - Annual Review of Pharmacology and …, 2019 - annualreviews.org
The motor symptoms of Parkinson's disease (PD) mainly arise from degeneration of
dopamine neurons within the substantia nigra. As no disease-modifying PD therapies are …

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

S Duty, P Jenner - British journal of pharmacology, 2011 - Wiley Online Library
Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of
novel treatments for motor symptoms of PD and in the search for clues to the underlying …

Calcium and Parkinson's disease

DJ Surmeier, PT Schumacker, JD Guzman… - Biochemical and …, 2017 - Elsevier
Parkinson's disease (PD) is the second most common neurodegenerative disease in the
world. Its causes are poorly understood and there is no proven therapeutic strategy for …

Animal models of Parkinson's disease

F Blandini, MT Armentero - The FEBS journal, 2012 - Wiley Online Library
Animal models of Parkinson's disease (PD) have been widely used in the past four decades
to investigate the pathogenesis and pathophysiology of this neurodegenerative disorder …

Functional models of Parkinson's disease: a valuable tool in the development of novel therapies

P Jenner - Annals of Neurology: Official Journal of the …, 2008 - Wiley Online Library
Functional models of Parkinson's disease (PD) have led to effective treatment for the motor
symptoms. Toxin‐based models, such as the 6‐hydroxydopamine–lesioned rat and 1 …

Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against …

JN Joyce, S Presgraves, L Renish, S Borwege… - Experimental …, 2003 - Elsevier
The novel naphtoxazine derivative and preferential D3 vs D2 receptor agonist, S32504,
restores perturbed motor function in rodent and primate models of antiparkinsonian activity …

Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol

GE Meredith, S Totterdell, JA Potashkin… - Parkinsonism & related …, 2008 - Elsevier
Formidable challenges for Parkinson's disease (PD) research are to understand the
processes underlying nigrostriatal degeneration and how to protect dopamine neurons …

Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease

AHV Schapira - Neurology, 2009 - AAN Enterprises
During the last 20 years, an enormous research effort and hundreds of millions of dollars
have been spent attempting to develop and prove that drugs may slow the rate of …